Evidence map›Paper›PMID 37432365›Full record

ArticleBJS open2023

Oncological outcomes after pancreatoduodenectomy for pancreatic ductal adenocarcinoma in octogenarians: case-control study.

Rupaly Pande, Joseph A Attard, Bilal Al-Sarireh, Ricky Harminder Bhogal, Alexia Farrugia, Giuseppe Fusai, Simon Harper, Camila Hidalgo-Salinas, Asif Jah, Gabriele Marangoni and 8 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BJS open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 1 country.

Rupaly PandeHPB and Liver Transplant Unit, Queen Elizabeth Hospital, Birmingham, UK.
Joseph A AttardHPB and Liver Transplant Unit, Queen Elizabeth Hospital, Birmingham, UK.ORCID 0000-0001-5770-2896
Bilal Al-SarirehDepartment of Surgery, Morriston Hospital, Swansea, UK.
Ricky Harminder BhogalHPB Unit, Royal Marsden Hospital, London, UK.
Alexia FarrugiaDepartment of Surgery, University Hospitals Coventry and Warwickshire NHS trust, Coventry, UK.
Giuseppe FusaiHPB and Liver Transplant Unit, Royal Free Hospital, London, UK.
Simon HarperHPB Unit, Cambridge University Hospital, Cambridge, UK.
Camila Hidalgo-SalinasHPB and Liver Transplant Unit, Royal Free Hospital, London, UK.
Asif JahHPB Unit, Cambridge University Hospital, Cambridge, UK.
Gabriele MarangoniDepartment of Surgery, University Hospitals Coventry and Warwickshire NHS trust, Coventry, UK.
Matthew MortimerDepartment of Surgery, Morriston Hospital, Swansea, UK.
Michail PizaniasHPB Unit, King's College Hospital, London, UK.ORCID 0000-0002-5270-3555
Andreas PrachialiasHPB Unit, King's College Hospital, London, UK.
Keith J RobertsHPB and Liver Transplant Unit, Queen Elizabeth Hospital, Birmingham, UK.
Chloe Sew HeeHPB Unit, Cambridge University Hospital, Cambridge, UK.
Fiammetta SoggiuHPB and Liver Transplant Unit, Royal Free Hospital, London, UK.ORCID 0000-0003-2317-7776
Parthi SrinivasanHPB Unit, King's College Hospital, London, UK.
Nikolaos A ChatzizachariasHPB and Liver Transplant Unit, Queen Elizabeth Hospital, Birmingham, UK.
Queen Elizabeth Hospital Birmingham · GBKing's College Hospital · GBThe Royal Free Hospital · GBUniversity of Cambridge · GBMorriston Hospital · GBUniversity Hospitals Coventry and Warwickshire NHS Trust · GBRoyal Marsden Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBy the end of this decade, 70 per cent of all diagnosed pancreatic ductal adenocarcinomas will be in the elderly. Surgical resection is the only curative option. In the elderly perioperative mortality is higher, while controversy still exists as to whether aggressive treatment offers any survival benefit. This study aimed to assess the oncological benefit of pancreatoduodenectomy in octogenarians with pancreatic ductal adenocarcinoma.

methodRetrospective multicentre case-control study of octogenarians and younger controls who underwent pancreatoduodenectomy for pancreatic ductal adenocarcinoma between 2008 and 2017. The primary endpoint was overall survival and the secondary endpoint was disease-free survival.

resultsOverall, 220 patients were included. Although the Charlson co-morbidity index was higher in octogenerians, Eastern Cooperative Oncology Group performance status, ASA and pathological parameters were comparable. Adjuvant therapy was more frequently delivered in the younger group (n = 80, 73 per cent versus n = 58, 53 per cent, P = 0.006). There was no significant difference between octogenarians and controls in overall survival (20 versus 29 months, P = 0.095) or disease-free survival (19 versus 22 months, P = 0.742). On multivariable analysis, age was not an independent predictor of either oncological outcome measured.

conclusionOctogenarians with pancreatic ductal adenocarcinoma of the head and uncinate process may benefit from comparable oncological outcomes to younger patients with surgical treatment. Due to the age- and disease-related frailty and co-morbidities, careful preoperative assessment and patient selection is of paramount importance.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAgedAged, 80 and overCase-Control StudiesHumansOctogenariansPancreaticoduodenectomy

Identifiers

PMID37432365
PMCPMC10335165
OpenAlexW4383872988

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.